Dermatol. praxi. 2023;17(2):88-90 | DOI: 10.36290/der.2023.014

Psoriasis and inflammatory bowel disease

MUDr. Kristína Gibalová
Dermatovenerologická klinika, Fakultní nemocnice Královské Vinohrady, Praha

Psoriasis is a chronic inflammatory non-infectious skin disease with a multifactorial etiology. It can occur along with other immune-mediated diseases, including non-specific intestinal inflammation. Our understanding of the underlying pathogenetic mechanisms has deepened substantially in recent decades and is developing together with new therapies targeting pathways and pro-inflammatory cytokines that have been described in association with the disease. Psoriasis and IBD not only have significant overlap, but there are also differences that affect therapy.

Keywords: psoriasis, inflammatory bowel disease, therapy.

Accepted: June 1, 2023; Published: June 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gibalová K. Psoriasis and inflammatory bowel disease. Dermatol. praxi. 2023;17(2):88-90. doi: 10.36290/der.2023.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Investig. Dermatol. 2013;133(2):377-385. Go to original source...
    2. Grän F, Kerstan A, Serfling E, et al. Focus: Skin: Current Developments in the Immunology of Psoriasis. ale J. Biol. Med. 2020;93(1):97.
    3. Baumgart DC, Sandborn W J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-1657. Go to original source...
    4. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum. Mol. Genet. 1997;6(8):1349-1356. Go to original source... Go to PubMed...
    5. Lee I, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am. J. Gastroenterol. (Springer Nature). 1990;85(8):962-963. Go to PubMed...
    6. Lolli E, Saraceno R, Calabrese E, et al. Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study. J. Crohn's Colitis. 2015;9(9):699-707. Go to original source...
    7. Vlachos C, Gaitanis G, Katsanos KH, et al. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis: Targets and Therapy. 2016;6:73-92. Go to original source...
    8. Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br. J. Dermatol. 2021;184(1):14-24. Go to original source...
    9. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 2019;20(6):1475. Go to original source...
    10. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J. Eur. Acad. Dermatol. Venereol. 2008;23(5):561-565. Go to original source...
    11. Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. BioMed Res. Int. 2013. Go to original source...
    12. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 2009;41(12):1335-1340. Go to original source... Go to PubMed...
    13. Kanwar A, Yadav S, Dogra S. Psoriasis: What is new in nonbiologic systemic therapy in the era of biologics? Indian J. Dermatol. Venereol. Leprol. 2010;76(6):622. Go to original source... Go to PubMed...
    14. Hoentjen F, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis. Current gastroenterology reports. 2011;13(5):475-485. Go to original source...
    15. Hedin CRH, Sonkoly E, Eberhardson M, et al. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J. Intern. Med. 2021;290(2):257-278. Go to original source...
    16. Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J. Crohn's Colitis. 2012;6(5):518-523. Go to original source...
    17. Hanžel J, D'Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin. Biol. Ther. 2020; 20(4):399-406. Go to original source... Go to PubMed...
    18. Sandborn WJ, D'Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn's disease: induction results from the Phase 2 GALAXI-1 study. Gastroenterology. 2022; 162(6):1650-1664. Go to original source...
    19. Yiu ZZ, Griffiths CE. Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev. Clin. Immunol. 2016;12(1):1-4. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.